Fig. 1From: Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trialEnrollment, interventions and assessments in the Vigip-SEP studyBack to article page